

Systematic Review

Optical Methods for Brain Tumor Detection: A Systematic Review

Gustav Burström¹, Misha Amini¹, Victor Gabriel El-Hajj¹, Arooj Arfan¹, Maria Gharos¹, Ali Buwaider¹,
Merle S. Losch², Francesca Manni³, Erik Edström^{1,4,5} and Adrian Elmi-Terander^{1,4,5,6,*}

- ¹ Department of Clinical Neuroscience, Karolinska Institute, 171 77 Stockholm, Sweden; gburstrom@gmail.com (G.B.); misha.amini@stud.ki.se (M.A.); arooj.arfan@stud.ki.se (A.A.); mcg02@mail.aub.edu (M.G.); ali.buwaider@stud.ki.se (A.B.); erik.edstrom.1@ki.se (E.E.)
- ² Department of Biomechanical Engineering, Faculty of Mechanical Engineering, Delft University of Technology, 2627 Delft, The Netherlands
- ³ Department of Electrical Engineering, Eindhoven University of Technology (TU/e), 5612 Eindhoven, The Netherlands; f.manni@tue.nl
- ⁴ Capio Spine Center Stockholm, Löwenströmska Hospital, 194 80 Upplands-Väsby, Sweden
- ⁵ Department of Medical Sciences, Örebro University, 701 85 Örebro, Sweden
- ⁶ Department of Surgical Sciences, Uppsala University, 751 35 Uppsala, Sweden
- * Correspondence: adrian.elmi.terander@ki.se

Abstract: Background: In brain tumor surgery, maximal tumor resection is typically desired. This is complicated by infiltrative tumor cells which cannot be visually distinguished from healthy brain tissue. Optical methods are an emerging field that can potentially revolutionize brain tumor surgery through intraoperative differentiation between healthy and tumor tissues. **Methods:** This study aimed to systematically explore and summarize the existing literature on the use of Raman Spectroscopy (RS), Hyperspectral Imaging (HSI), Optical Coherence Tomography (OCT), and Diffuse Reflectance Spectroscopy (DRS) for brain tumor detection. MEDLINE, Embase, and Web of Science were searched for studies evaluating the accuracy of these systems for brain tumor detection. Outcome measures included accuracy, sensitivity, and specificity. **Results:** In total, 44 studies were included, covering a range of tumor types and technologies. Accuracy metrics in the studies ranged between 54 and 100% for RS, 69 and 99% for HSI, 82 and 99% for OCT, and 42 and 100% for DRS. **Conclusions:** This review provides insightful evidence on the use of optical methods in distinguishing tumor from healthy brain tissue.

Keywords: neuro-oncology; optical coherence tomography; diffuse reflectance spectroscopy; hyperspectral imaging; Raman spectroscopy; accuracy; review



Citation: Burström, G.; Amini, M.; El-Hajj, V.G.; Arfan, A.; Gharos, M.; Buwaider, A.; Losch, M.S.; Manni, F.; Edström, E.; Elmi-Terander, A. Optical Methods for Brain Tumor Detection: A Systematic Review. *J. Clin. Med.* **2024**, *13*, 2676. <https://doi.org/10.3390/jcm13092676>

Academic Editor: Massimiliano Visocchi

Received: 11 April 2024
Revised: 28 April 2024
Accepted: 30 April 2024
Published: 2 May 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

In brain tumor surgery, the extent of resection of tumors has significant implications on relapse, overall survival, quality of life, and the need for adjuvant or salvage therapy [1,2]. The burden of locoregional tumor recurrence resulting from tumor remnants after surgery is vast and often inevitable in malignant tumor types [3]. Consequently, gross total resection is generally the aim of brain tumor surgery, with exemptions in eloquent areas of the brain. However, tumor borders are rarely sharp, as infiltration into healthy brain tissue is common in malignant brain tumors. The inability to accurately visualize tumor borders during operation hence threatens the balance between gross total resection of tumor tissue and preservation of healthy brain tissue [4,5]. Technologies that aim to optimize the extent of resection by offering tissue demarcation capabilities are hence highly relevant to the field. Image-guided neuronavigation, 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery, intraoperative ultrasound guidance, and intraoperative MRI are some of the most employed technologies for this purpose [5,6]. Whilst all these technologies have various

degrees of reported benefit in optimizing the extent of resection during surgery [7–9], they offer macroscopic visibility only.

Neuronavigational techniques rely on preoperative MR images, leading to decreased accuracy as brain shift and brain deformation during surgery cause tumor boundaries to shift [10]. Intraoperative MRI solves the brain shift problem but faces challenges due to poor spatial resolution, high cost and increased operation time [11]. Intraoperative ultrasound is affordable but is limited due to image artefacts and challenging patient positioning, making it difficult to standardize and interpret [12]. Finally, fluorescence-guided techniques such as 5-ALA are invasive, show variable uptake of contrast among patients [13] and have low utility in certain anatomical locations [14]. These fluorescence-guided techniques are most accurate when targeting contrast-enhancing disease with high cellularity, making them suboptimal in many patient groups where resection of non-enhancing tissue has been shown to improve long-term survival [15]. While improvement of these technologies may be an option, the development of more advanced, and reliable tools certainly merits further investigation.

Intrinsic optical imaging techniques are emerging as one of the most promising frontiers in the field [16–19]. These minimally invasive, label-free techniques directly detect tumor infiltration based on the biochemical properties of the tissue and, in some cases, with sub-micron resolution. Each tissue has an individual optical “fingerprint” depending on its microstructure, cellular and mitochondrial density, molecular composition, presence of natural pigments (e.g., hemoglobin, beta-carotene, melanin), and pathological or physiological factors such as vascularization or necrosis, etc. [20]. There are various tools used for the detection of different parameters of light reflection, all of which utilize different intrinsic optical concepts.

These methods have long been applied in preclinical settings [21]. The more recent advances in computational power, machine learning, data processing and optical fiber technologies have now propelled the field towards human-based clinical studies [22,23]. Some of the most widely used and currently investigated optical methods specifically for applications in brain tumor surgery include Multispectral/Hyperspectral Imaging, Raman Spectroscopy, Optical Coherence Tomography and Diffuse Reflectance Spectroscopy, each individually presented below.

1.1. Raman Spectroscopy

Of the intrinsic optical methods, Raman spectroscopy is one of the most established within medical research. The method is based on the Raman effect, which was discovered in 1928 by C.V. Raman and K.S. Krishnan [24]. When subjected to a high intensity laser source, a molecule will scatter the incident light. Elastic photon scattering, also called Rayleigh scattering, occurs when the wavelength of the incident photon is the same as the scattered photon after interacting with the tissue. The Raman effect refers to a small percentage of photons (1:10 million) that undergo inelastic scattering and change wavelength by either absorbing from or losing energy to the tissue. The resulting Raman spectrum serves as a unique chemical fingerprint of the tissue [24].

In biological tissues, the vibrational modes of different molecules in the tissue in combination with the composition of nucleic acids, proteins, and lipids, give the tissue a specific spectrum of Raman scattering [25]. Utilizing sophisticated spectroscopic techniques together with laser excitation, the Raman scattering can be detected and converted into spectral data for the material observed [26].

Raman spectroscopy has proven to be a well-suited technique for characterization of biological tissues such as tumors [16,27]. It is non-invasive, simple to operate and requires minimal sample preparation compared to previous techniques, e.g., 5-ALA [13]. Within brain tumor surgery, the Raman-based methods can be used for improving diagnostics of brain tumor biopsies [28], in Vivo tumor detection [29], molecular classification [30] and intraoperative histopathologic characterization [31]. The Raman-based imaging approaches that are most broadly used in neurosurgery include: stimulated Raman spectroscopy (SRS),

stimulated Raman histology (SRH) and coherent anti-Stokes Raman scattering microscopy (CARS) [32].

There are still obstacles to overcome. Since only one in ten million photons is Raman scattered, the technique faces challenges in detecting low sample concentrations, especially in the context of competing phenomena such as elastic scattering and absorption effects. Besides the intrinsically weak Raman signal, other limitations include limited imaging depth, a limited field of view as well as slow imaging speed [33]. Hence, measuring the Raman effect requires sophisticated optical technologies to be compatible with the neurosurgical workflow. Pioneering research is underway to develop such technologies, with recent additions such as handheld fiber-optic Raman probes which can distinguish cancer from healthy brain, with high sensitivity and specificity [34]. These probes operate in real-time, requiring <0.2 s to measure spectra and have shown to be easily integrated into the neurosurgical workflow.

Raman spectroscopy can thus provide diagnostic information in a shorter time compared to histopathology, the current gold standard for tissue diagnostics. RS data is acquired and processed within seconds, while intrasurgical histopathology takes tens of minutes [35].

1.2. Hyperspectral Imaging

Multispectral and hyperspectral imaging are spectral-based imaging modalities that acquire data in almost contiguous narrow spectral bands. They allow the capture and interpretation of wavelengths and color bands beyond our physiological capability (which is a narrow range consisting of three color bands—red (620–750 nm), green (495–570 nm) and blue (450–495 nm)). The difference between multispectral and hyperspectral lies in the count and width (nm) of the scanned wavelength range: hyperspectral includes bands with narrow widths (10–20 nm) and up to hundreds or thousands of them, whereas multispectral includes three to ten wider bands. From now on, we will refer to them both as “hyperspectral imaging”.

The spatial and spectral data extracted in hyperspectral imaging is presented as a three dimensional (3D) hyperspectral data cube, which forms a set of 2D images [36]. Each pixel in the 2D plane provides a unique spectral signature reflecting the chemical composition of that particular pixel [37]. These 3D cubes serve as input for different computational techniques for visualizing and interpreting the data to differentiate different tissues [19]. With the recent progress in machine learning algorithms, these technologies are raising interest for various applications within the neurosurgical field [19,38].

The primary benefit of this technology is that it only uses white light to acquire the wavelengths of interest, thereby detecting spectral information in a non-invasive, non-ionizing way and without any physical contact [19]. The ability to obtain real-time hyperspectral images is crucial and suits intraoperative surgical use. In addition to differentiating between healthy and tumor brain tissue [39,40], hyperspectral imaging has been used to monitor intra-operative tissue oxygenation [41] as well as create real-time anatomical maps of the surgical space in other organs [42]. Despite these capabilities, the technique is not in regular surgical use yet due to lagging hardware development. More research is needed to miniaturize hyperspectral sensors and develop adequate real-time imaging models.

1.3. Optical Coherence Tomography

Optical Coherence Tomography is an established optical imaging technique that has been implemented in clinical practice within medical specialties including cardiology [43], dermatology [44], and neurosurgery [45]. One of the first areas of application was ophthalmology, where it was first used for in vivo retinal imaging by Fercher et al. [46].

OCT is a non-invasive, label-free, and cost-effective technique, capable of providing high-resolution, continuous, and three-dimensional tissue imaging [18]. It is based on utilization of broad-bandwidth light sources and interferometry with a low coherence length.

The emitted light is coupled into an interferometer, a device that extracts information from interference. There are two light arms in the system, a sample arm, and a reference arm. The sample arm emits light toward the sample of interest, usually combined with an objective lens to focus the light, and the reference arm towards a mirror. Backscattered light from the sample and light from the reference are combined to generate an interference pattern that is detected by a detector. Two-dimensional or three-dimensional models are then reconstructed by scanning through the sample surfaces [47].

OCT can have image resolutions of 1–10 μm in all analyzed dimensions and is optimal for transparent or semi-transparent objects of limited depth, making it well suited for imaging biological tissue [48]. There is growing interest for OCT in neurosurgery as it can deliver continuous feedback to the surgeon with imaging depth (1.5–3 mm) that is comparable to resection depth for cancer-infiltrated brain tissue [49]. Currently the two main types of instruments used are handheld probes and microscope-integrated OCT systems [50,51]. These handheld probes demonstrate good resolution and field of view; while the microscope OCT-systems developed so far are very flexible, allowing an OCT-Camera to be attached to many different surgical microscopes.

1.4. Diffuse Reflectance Spectroscopy

Diffuse Reflectance Spectroscopy is an optical technology that is based on elastic scattering of light, as opposed to Raman, which is based on inelastic scattering. Elastic scattering occurs more frequently than inelastic scattering to a factor of roughly 10:1 [24]. This allows DRS to collect scattering data much faster than Raman spectroscopy, providing faster reading times intraoperatively. In DRS, the optical fiber probe collects light originally emitted by the illumination fiber after it is partially scattered back by the tissue. The partial scatter is a result of absorption, reflection, transmission, and scattering. The elastic scattering can be used for precise optical characterization of tissues [52]. The molecular composition of a tissue determines the light absorption and thus the DRS-fingerprint of the specific tissue. Light absorption is mainly related to the types and concentration of endogenous chromophores present within tissues (e.g., fat, water, collagen, hemoglobin, beta-carotene, melanin, myoglobin) [53].

All the four mentioned technologies are non-invasive and capable of providing real-time feedback during intraoperative setups. HIS, RS and DRS technologies can provide information about the bulk properties of the tissue, such as oxygenation and blood volume but also by detecting spectroscopic patterns unique to the studied tumors. RS typically works at a smaller scale (subcellular) as opposed to HIS and DRS. OCT offers an outstanding axial spatial resolution (1.5–3 mm), thereby approaching the spatial resolution of conventional histopathology.

In summary, given the ongoing technological advancements within the field of neurosurgery [54–56], the novelty of these techniques warrants a closer and systematic scrutiny to determine their potential added value. In an attempt to provide alternative technologies as a complement to current neuronavigational image-based and fluorescence-based solutions, this study aimed to investigate the use of four intrinsic optical imaging techniques, which already have evolved from pre-clinical settings to clinical applications in brain tumor surgery. We believe that these technologies have the highest potential for incorporation in modern decision support tools for neurosurgery. The aim of this systematic review is hence to compile evidence for the use of each of these techniques in brain surgery and to investigate their benefit in correctly distinguishing brain tumor tissue from healthy brain tissue. As a primary outcome, the synthesis will be focusing on sensitivity, specificity and accuracy data, as well as indicating the knowledge gaps that require further investigation and understanding.

2. Materials and Methods

This systematic review protocol was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) checklist from

2015 (Supplementary file S1, Table S1). For transparency, the protocol was registered in the International prospective register of systematic reviews (PROSPERO), an established and widely used platform [54,57–59] (ID: CRD42022335836, Date of registration: 7 June 2022). A summary of the search strategy has been provided (Supplementary file S1, Table S2).

2.1. Type of Studies

All original articles published in the English language were eligible for inclusion. Reviews, editorials, and letters to the editor were excluded. To maintain relevancy and adhere to recent knowledge, studies that were published prior to January 1990 were also excluded.

2.2. Type of Population

Studies performed on human brain tumor tissue, either in vivo or ex vivo were included. Tumor types include any intracranial tumors, ranging from primary benign or malignant tumors to brain metastases. For inclusion, at least five samples had to be included in the study's analysis.

2.3. Types of Intervention

Methods involving exogenous fluorescent molecules or histopathological dyeing were excluded. Only studies investigating optical methods relying on the intrinsic properties of the tissue were considered. The optical methods of interest were as follows: (1) Hyperspectral Imaging, (2) Raman Spectroscopy, (3) Optical Coherence Tomography, and (4) Diffuse Reflectance Spectroscopy. These methods were chosen based on a review of the literature that aimed to yield the most interesting techniques within the field, as well as from consultation of experts in the field.

2.4. Types of Comparators

The studies that were included used any of the following comparators: healthy brain control tissue or any other tumor type.

2.5. Types of Outcome Measures

The primary outcome of interest consisted of quantitative precision measures. These measures included sensitivity, specificity, and accuracy. All studies that did not report at least one of these quantitative precision measures were excluded.

2.6. Sources of Information and Search Strategy

Searches were performed on Medline (Ovid), Web of Science, and Embase using a combination of the keywords, "brain" and "tumor", with related entry terms specifically relating to each of the optical methods investigated (ex. "brain" "tumor" "diffuse reflectance spectroscopy").

2.7. Data Selection

The screening of articles was performed on the Rayyan software [54,57–61] by two independent and blinded reviewers (MA) and (GB). In the first stage of the screening process, titles and abstracts were screened and irrelevant articles were extracted. In the second stage, the full texts of the remaining articles were retained. The retained full texts were assessed for inclusion based on the mentioned eligibility criteria. Any discrepancy in the article selection process was resolved via discussion and unanimous decision.

2.8. Data Extraction

A data extraction template was designed to maintain a consistent extraction of data throughout the review (Supplementary file S1, Table S3).

2.9. Synthesis of Data

As the field of optical methods within brain tumor surgery is still unexplored, methodological heterogeneity in study design, data analysis, statistical methods, tumor types and diagnostic algorithms among the studies included was observed. Hence, it was not applicable to conduct a meta-analysis. Instead, a qualitative synthesis of the results of the included studies was performed, with a focus on study characteristics as well as outcomes in terms of sensitivity, specificity, and accuracy.

3. Results

The initial searches in Web of Science, Medline (Ovid), and Embase resulted in 488, 485, and 897 records, respectively. In total, 1870 records were obtained. Following the screening process, 44 articles were included in this systematic review (Figure 1).




Figure 1. PRISMA flow chart diagram.

3.1. Raman Spectroscopy

3.1.1. Study Characteristics

Raman spectroscopy (RS) was the most used with 31 studies (70.5%) investigating its use (Supplementary file S1, Table S4). Most of these studies were based in the US. Twenty-seven studies involved ex vivo tissues while only four performed optical analysis

on in vivo tissues. The numbers of patients/samples ranged from 8 to 278. The studies applied a variety of diagnostic algorithms for classification of spectral data, with principal components analysis being the most mentioned, followed by support vector machines and linear discriminant analysis. Glial tumors, including glioblastoma multiforme, astrocytoma, and oligodendrogliomas were the most investigated, followed by meningiomas, and brain metastases.

3.1.2. Study Outcomes

A large heterogeneity in terms of diagnostic accuracy was detected among the studies (Table 1). Overall, the reported sensitivity ranged from 24% (Stables et al. [62]) to 100% (Livermore et al. [63], Sun et al. [64], Leslie et al. [65]), the specificity from 19% (Stables et al. [62]) to 100% (Aguiar et al. [66], Sun et al. [64], Livermore et al. [59], Leslie et al. [65]), and accuracy from 54% (Stables et al. [62]) to 100% (Koljenovic et al. [67,68]).

Table 1. Study outcomes. Tables listing precision outcomes in terms of sensitivity, specificity, and accuracy for RS studies.

Study	Classifier	Sensitivity %		Specificity %		Accuracy %	
Riva et al. [69]	Normal vs. glioma	N/A		N/A		RF 80	GB 83
Sciortino et al. [70]	IDH-mut vs. IDH-wildtype	N/A		N/A		RBF-SVM 87	XGB 85
Kopeck et al. [71]	MET	95	86				
	GS	95	50				
	AOD III	100	99				
	MEN II	90	80				N/A
	MT	90	92				
	PT	96	62				
	NF	90	73				
Jelke et al. [72]	Meningioma vs. dura	Cross-validated 96	Hold-out external validation 100	Cross-validated 95	Hold-out external validation 94	N/A	
Pekmezci et al. [73]	Raman vs. H&E Raman vs. IHC Assessment of WHO-grade	Raman vs. H&E = 86 Raman vs. IHC = 88		Raman vs. H&E = 86 Raman vs. IHC = 81		WHO II = 81 (by specimen) WHO II-IV = 81 (by specimen) WHO II = 100 (by patient) WHO II-IV = 73 (by patient)	
Aguiar et al. [66]	G vs. Cerebellum	LDA 96	PLS-DA 98	LDA 91	PLS-DA 97	LDA 93	PLS-DA 98
	MEN vs. Meninges	99	99	100	100	99	99
	Combined						94
Livermore et al. [63]	Tumor	96	99				99
	Normal brain	99	96				99
	Raman (overall)	100	100				100
Bury et al. 1 [74]	Normal vs. tumor (MEN and G)	PCA-QDA 99		PCA-QDA 42		PCA-QDA 94	
Hollon et al. 1 [75]	Raman Pathologist	N/A		N/A		95 94	
Bovenkamp et al. [76]	Pathological tissue vs. pituitary gland tissue						
	Corticotroph						84
	Gonadotroph						88
	Somatotroph						99
	Plurihormonal						91
	Null cell						91
	Pituitary gland Periosteal layer						95 100
Sun et al. [64]	wavenm/cm ⁻¹ Normal vs. Tumor	350–2000	1200–1600	350–2000	1200–1600	350–2000	1200–1600
	PLS	100	100	100	100	100	100
	SVM	91	96	100	100	96	98
	ANN	100	100	91	100	94	100
Morais et al. [77]		PCA-LDA, SPA-QDA 86		PCA-LDA, SPA-QDA2 100		PCA-LDA, SPA-QDA 96	

Table 1. Cont.

Study	Classifier	Sensitivity %		Specificity %		Accuracy %		
Galli et al. [78]	Tumor vs. non-tumor Spectra Biopsy	N/A		N/A		93 95		
Uckermann et al. [30]	IDH-mut vs. IDH-wt Validation set Training set	N/A		N/A		89 88		
Bury et al. 2 [79]	vs each other Colon Lung Melanoma Colon+lung vs. melanoma Colon+Lung Melanoma	N/A		N/A		69 69 72 85 75		
Hollon et al. 2 [80]	Normal vs. lesional tissue Low-grade vs. high-grade	N/A		N/A		94 89		
Jermyn et al. 1 Integrated [81]	G vs. normal MET vs. normal combined vs. normal	RS 90 97 92	RS+IFS 100 100 100	RS 97 84 90	RS+IFS 94 92 93	RS 93 90 91	RS+IFS 98 96 97	
Stables et al. [62]	Normal MET GBM	N/A		N/A		71 87 54		
Jermyn et al. 2 [82]	Invasive cancer vs. normal	92		93		92		
Liu et al. [83]	Normal vs. Glioma Glioma vs. Normal	N/A		N/A		86 89		
Jermyn et al. 3 [84]	Normal vs. all cancer	93		91		92		
Desroches et al. [29]	Vital (tumor and normal) vs. Necrosis	84		89		87		
Ji et al. [85]	Raman H&E Tumor infiltrated vs. non tumor Glioma-only GAM Leave-one-out cross-validation	98 97 87		99 99 88		95 92		
Kalkanis et al. [86]	Necrosis vs. normal vs. GBM Training set Validation set	N/A		N/A		98 100		
Bergner et al. [87]	Carcinoma vs. normal brain vs. necrosis vs. "remaining" 1st level training data 1st level independent data 2nd level training data 2nd level training data	N/A		N/A		Linear SVM 95 95 100 80	Radial SVM 97 93 100 89	PLS-DA 88 94 97 70
Auner et al. [88]	Normal vs. MB vs. G Training Testing Combined classification	N/A		N/A		95 89 97		
Leslie et al. [65]	A vs. normal Low-grade EP vs. normal Low-grade G vs. normal OD vs. normal Tissue level Low-grade G vs. high-grade G Low-grade EP vs. high-grade Training All Testing normal G MB Differentiation A EP OD GG	87 92 92 100 91 100		98 99.7 98 100 100 87 96 92		100 85 89 61 75		
Koljenovic et al. 1 [67]	MEN vs. dura	N/A		N/A		LDA 100		
Koljenovic et al. 2 [68]	Necrotic vs. vital	N/A		N/A		LDA 100		

Table 1. Cont.

Study	Classifier	Sensitivity %	Specificity %	Accuracy %
Zhou et al. [89]	Glioma vs. Normal	100	96.3	99.6
Baria et al. [35]	Raman alone			
	Control vs. Tumor	92.6	93.3	82.5
	Control vs. Dysplasia	76.6	80	
	Tumor vs. Dysplasia	66.7	77.7	
	Multimodal approach			87.5
	Control vs. Tumor	91	100	
	Control vs. Dysplasia	86	100	
	Tumor vs. Dysplasia	89	86	

Abbreviations: N/A = Not applicable. **Tumors:** A = Astrocytoma; AA = Anaplastic astrocytoma; AE = Anaplastic ependymoma; AG = Astroganglioma; AOD = Anaplastic oligodendroglioma; E = Embryonal; EP = Ependymoma; G = Glioma; GBM = glioblastoma; GG = Ganglioglioma; GM = Germinoma; GS = Gliosarcoma; HB = Hemangioblastoma; M = Meningioma; MB = Medulloblastoma; Met = Metastasis; MT = Meningothelioma; N = Normal; NF = Neurofibroma; OA = Oligoastrocytoma; OD = Oligodendroglioma; PA = Pilocytic astrocytoma; PT = Pituitary. **Diagnostic algorithms:** ANN = Artificial Neural Network; Bt = Boosted trees; CNN = Convolutional Neural Network; DA = Discriminant analysis; DFA = Discriminant Function Analysis; DNN = Deep Neural Networks; GAM = Generalized additive model; Gb = Gradient Boosting; KCA = K-means Cluster Analysis; KNN = K- Nearest Neighbour classifier; kNN = kernel Neural Network; LDA = Linear Discriminant analysis; PC = Principal Components; PCA = Principal Component Analysis; PLS = Partial least squares; QDA = Quadrantic Discriminant Analysis; RBF = Radial Basis Function kernel; RF = Random Forrest; SPA = Successive Projections Algorithm; SVM = Support Vector Machine; and XGB = eXtreme Gradient Boosted trees.

3.2. Hyperspectral Imaging (HIS)

3.2.1. Study Characteristics

Five studies investigating HIS were included (Supplementary file S1, Table S5). Four of these studies involved the same research group based in Spain. Four studies used the same Hyperspectral Imaging system (Hyperspec[®]VNIR A-Series, Headwall Photonics Inc., Fitchburg, MA, USA). While four of the studies analyzed images in an in vivo setting, one study analyzed ex vivo tissue samples. All of the studies involved the analysis of normal brain tissue as a comparator. Six different diagnostic algorithms were used across studies, all yielding different results. Urbanos et al. [90] and Ortega et al. [91] both used the conventional support vector machine (SVM), random forest (RF), convolutional neural networks (CNN), and artificial neural networks (ANN). In two of their articles, Fabelo et al. focused on 1D-CNN and 2D-CNN methods [92,93], while Manni et al. [94], in their study, proposed a 2D-3D-CNN hybrid model.

3.2.2. Study Outcomes

Sensitivity values ranging from 32% (Urbanos et al. [90]) to 98% (Ortega et al. [91]) and specificity values from 71% (Ortega et al. [91]) to 100% (Fabelo et al. [92], Fabelo et al. [93]) were reported among the included studies (Table 2). The best performing diagnostic algorithms in terms of accuracy were RF (Urbanos et al. [90] and Ortega et al. [91]) as well as 1D-DNN (Fabelo et al. [92,93]).

Table 2. Study outcomes. Table listing precision outcomes in terms of sensitivity, specificity, and accuracy for HIS studies.

Study	Tissue	Sensitivity %			Specificity %			Accuracy %		
		SVM (A)	RF (A)	CNN (A)	SVM (A)	RF (A)	CNN (A)	SVM (A)	RF(A)	CNN(A)
Urbanos et al. [90]	Overall							75	95	92
	Healthy	90	98	98	72	95	89	81	97	94
	Tumor	32	86	63	91	99	99	80	97	94
	Dura	79	97	96	96	99	99	93	99	99
Manni et al. [94]		2D-3D CNN (hybrid)			2D-3D CNN (hybrid)					
	Mean									
	Normal		76			87		2D-3D CNN (hybrid)		
	Tumor		68			98		80		
	Vessel		74			92				
Background		87			87					
Fabelo et al. 1 [92]		1D-DNN	2D-CNN		1D-DNN	2D-CNN	1D-DNN	2D-CNN		
		88	76		100	100	94		88	

Table 2. Cont.

Study	Tissue	Sensitivity %			Specificity %			Accuracy %		
		1D-DNN	2D-CNN	RF	1D-DNN	2D-CNN	RF	1D-DNN	2D-CNN	RF
Fabelo et al. 2 [93]		88	76		100	100		95	90	
		SVM	ANN	RF	SVM	ANN	RF	SVM	ANN	RF
Ortega et al. [91]	(Tumor vs. normal)									
	Self as control	96	98	96	97	98	97	96	98	96
	Others + self as control	86	92	94	79	91	92	83	92	93
	Others as control	76	75	73	71	77	79	76	78	69

Abbreviations: ANN = Artificial Neural Networks, CNN = Convolutional Neural networks, DNN = Deep Neural Networks, RF = Random Forrest, and SVM = Support Vector Machines.

3.3. Optical Coherence Tomography (OCT)

3.3.1. Study characteristics

A total of four studies on OCT were included in this review (Supplementary file S1, Table S6). These studies were based in the USA, Russia, and Germany. Möller et al. [95] and Kut et al. [96] studied ex vivo human samples, Juarez-Chambi et al. [97] focused on in vivo samples, while Yashin et al. studied both ex vivo and in vivo tissues [98]. The largest patient population was seen in Yashin et al. [98]. The tumors investigated in these articles included metastases, astrocytomas, low-grade gliomas, and glioblastoma multiforme. Various OCT-setups were used, including SD-OCT, TD-OCT, and cross polarization OCT (CP-OCT). All studies included the analysis of normal brain tissue as a control.

3.3.2. Study Outcomes

The study outcomes are summarized Table 3. In the study by Yashin et al. [98], the combination of both co-polarization and cross-polarization setups yielded a higher accuracy (87–88%) when compared to the separate accuracy of each of the two systems. Juarez-Chambi et al. [97] reported the precision of their system in distinguishing low-grade from high-grade tumors, achieving sensitivity and specificity of 91% and 83%, respectively (Table 3). The highest accuracy in the study by Möller et al. [95] (99%), was achieved when distinguishing healthy from necrotic tissue.

Table 3. Study outcomes. Table listing precision outcomes in terms of sensitivity, specificity, and accuracy for OCT studies.

Study	Classifier	Sensitivity %	Specificity %	Accuracy %
Möller et al. [95]	Vital tumor vs. healthy			96
	Healthy vs. necrosis	N/A	N/A	99
	Tumorous (vital + necrosis) vs. healthy			97
Yashin et al. [98]	Visual assessment of pics ex vivo			
	co-polarization	89–93	67–73	83–84
	cross polarization	80–87,	75–89	82–83
	combined	82–85	92–94	87–88
Juare-Chambi et al. [97]	Threshold of 80% determined by Receiver Operating Characteristic (ROC) analysis:			
	Low grade vs. non-cancerous	90%	81	N/A
	High grade vs. non-cancerous	95%	82	
	Low grade vs. high grade	91%	83	
Kut et al. [96]	Using optical attenuation threshold of 5.5 mm ⁻¹			
	High grade = 92%	92	100	N/A
	Low grade = 100%	100	80	

Abbreviations: N/A = Not applicable.

Overall sensitivity values for the OCT studies ranged from 80% (Yashin et al. [98]) to 100% (Kut et al. [96]), specificity values ranged from 67% (Yashin et al. [98]) to 100% (Kut et al. [96]) and accuracy values from 82% (Yashin et al. [98]) to 100% (Kut et al. [96]).

3.4. Diffuse Reflectance Spectroscopy (DRS)

3.4.1. Study Characteristics

Four DRS studies were included in this review (Supplementary file S1, Table S7). Three of these studies originated from the USA and one from Canada. Two of the studies shared the same first author (Lin et al. [99,100]). All articles used a system which employed a hand-held fiber optic probe.

Except for the study by Du Le et al. [101], where ex vivo samples were analyzed, all other studies involved in vivo samples. The number of patients ranged from 7 to 35 with the largest sample being represented in the study by Majumder et al. [102] The tumor tissues analyzed included several types of gliomas and metastases. In the studies by Lin et al. [99,100], multiple pediatric brain tumors were studied.

3.4.2. Study Outcomes

The study outcomes are summarized in Table 4. In the study by Du Le et al. [101], sensitivity and specificity of 100% and 90% were achieved by the DRS-based system when attempting to differentiate GBM from low-grade gliomas (Table 4). Majumder et al. [102] and Lin et al. [100] (2) studied the precision in detecting tumor margins from healthy brain tissue. Majumder et al. [102] applied two different diagnostic algorithms: maximum representation and discrimination feature-sparse multinomial logistic regression (MRDF-SMLR) and nearest-mean classifier (NMC). They reached accuracies of 94% in detecting tumor margins in MRDF-SMLR and 53% with NMC when running their validation sets.

Moreover, Lin et al. [100] (2) used both a single-step and a two-step discrimination algorithm in conjunction with the DRS system. When delineating tumor margins from a background of healthy brain tissue, the single-step discrimination algorithm yielded a sensitivity of 78% and a specificity of 76%, whereas the two-step discrimination algorithm achieved a slightly higher sensitivity: 89% and 76% for sensitivity and specificity, respectively.

Overall, the sensitivity of the DRS studies ranged from 75% in the second study by Lin et al. [100] to 100% in the study by Du Le et al. [101], while specificity ranged from 66% in the first study Lin et al. [99] to 90% in the one by Du Le et al. [101] Accuracy was only reported in the study by Majumder et al. [102] ranging from 42% to 100%, depending on the comparators considered.

Table 4. Study outcomes. Table listing precision outcomes in terms of sensitivity, specificity, and accuracy for DRS studies.

Study	Classifier	Sensitivity %	Specificity %	Accuracy %
Du Le et al. [101]	GBM vs. LGG 650 nm Cut-off			
	20% DR	100	80	N/A
	0.6 cm ⁻¹	92	80	
10 cm ⁻¹ at	100	90		
Lin et al. 1 [99]	Tumor vs. normal	95	66	N/A
Majumder et al. [102]	MRDF-SMLR	N/A	N/A	
	Training set			
	Tumor			96
	Tumor margin			80
	Normal			97
	Validation set			
Tumor	96			
Tumor margin	94			
Normal	100			
	NMC			

Table 4. Cont.

Study	Classifier	Sensitivity %	Specificity %	Accuracy %	
Majumder et al. [102]	MRDF-SMLR	N/A	N/A		
	Training set				
	Tumor			49	
	Tumor margin			78	
	Normal			52	
	Validation set				
Lin et al. 2 [100]	Tumor	42			
	Tumor margin	53			
	Normal	49			
	Discrimination algorithm	Single-step	Two-step	Single-step	Two-step
	Normal vs. infiltrative tumor margin	81	100	76	-
	Normal vs. primary tumors				
Lin et al. 2 [100]	Normal vs. secondary tumors	75	84	-	-
	Overall	83	-	-	-
		78	89	76	76

Abbreviations: N/A = Not applicable. Tumor: GBM = glioblastoma multiforme, LGG = low-grade glioma. Diagnostic algorithm: MRDF-SMLR = Maximum representation and discrimination feature-sparse multinomial logistic regression, and NMC = Nearest mean classifier.

4. Discussion

In this systematic review, the literature has been explored to search for data on the sensitivity, specificity, and accuracy of detecting human brain tumor tissue of four emerging optical methods (RS, HIS, OCT and DRS). The main aim was to identify studies that reported sensitivity, specificity, and accuracy on the precision of the optical methods. From these results it can be concluded that RS is clearly the most explored of the four technologies, whereas HIS, OCT and DRS are less examined. Moreover, studies that report significant levels of precision for distinguishing brain tumor from healthy tissue, using technologies based on these optical methods have been presented.

4.1. Raman Spectroscopy

Stables et al. [62] reported the lowest ratings in all three measures of sensitivity, specificity, and accuracy. This study used a method that generated and analyzed sound waves based on Raman spectra to distinguish between healthy and brain tissue. This alternative approach is worth exploring further as it can provide real-time auditory feedback to the neurosurgeon, without distracting their visual attention. However, improvement is needed regarding sensitivity and specificity. Eventual challenges including noise interference and user training must also be tackled before clinical implementation.

Studies reporting higher sensitivity and specificity measures used the conventional optical approach to decipher RS data (Jermyn et al. [81,82,84], Livermore et al. [63]). Applying their RS model on brain biopsies taken from patients who underwent supramaximal glioma resections, Livermore et al. [63] could report that most of these biopsies contained infiltrating tumor cells despite supramaximal resections. They further compared the performance of RS to 5-ALA in these margin biopsies, where 5-ALA-induced fluorescence failed to detect most of the infiltrating tumor cells. These results highlight the better precision RS provides and how it can be utilized to guide the surgeon in the critical tumor margin region.

One of the latest studies (Baria et al. [35]) compared individual spectroscopic techniques with a multimodal approach (combining fluorescence, RS and DRS) to differentiate between brain tumor cells and dysplastic cells, reporting a higher accuracy with the multimodal approach compared to RS alone. Multimodal approaches can provide a more comprehensive evaluation of the examined tissue by exploiting different biological features, making them a promising avenue for future exploration. Another extensively researched area in the field is the use of machine learning. RS data is being used to train robust machine

learning algorithms that can provide rapid and expert-level intraoperative diagnosis of brain tumors, practically replacing a traditional pathology laboratory (Hollon et al. [75,80]).

A main reason for all this success is the many new tumor biomarkers being identified using RS data. The heterogeneity found in brain cancer requires a wide range of molecular fingerprints to distinguish different tumor types. In the studies included here Stables et al. [62] reported increased choline content in glioblastoma tissue while tryptophan and 2-hydroxyglutarate (2HG) activity was correlated with gliomas (Stables et al. [62], Sun et al. [64]). In order to discriminate between low- and high-grade gliomas, RS markers for low-grade glioma include proline/tyrosine and choline/cholesterol, while phenylalanine and tryptophan are linked to high-grade gliomas [103]. Medulloblastoma has been shown to demonstrate a rise in the lipid-to-protein ratio when compared with normal brain tissue [104]. RS data have also demonstrated a conformational change from α -helix to β -sheets during tumor progression [104]. Hence, beyond guiding intraoperative tumor resection, RS is also contributing significantly to the field of neuro-oncology by detecting new tumor biomarkers.

4.2. Hyperspectral Imaging

Urbanos et al. [90] and Ortega et al. [91] reported contrasting differences in sensitivity values despite training their models with similar ML algorithms and on the same tumor type, glioblastoma. Both studies utilized supervised ML algorithms including SVM, RF, CNN and ANNs. However, Urbanos et al. [90] acquired their data from in vivo images obtained during surgery while Ortega et al. [91] used ex vivo pre-diagnosed Glioblastoma pathology slides.

Urbanos et al. [90] reported much lower sensitivity as the in vivo data showed high similarities between healthy and tumor glioblastoma tissue. This can be expected in the case of infiltrative tumors like glioblastoma where the healthy-labelled tissue is not always completely healthy. On the other hand, the same algorithms reported much higher sensitivity when trained on ex vivo tissue (Ortega et al. [91]). This variation in results is likely to be multifactorial, depending on tissue state, tissue labelling, and the ML model used, as studies combining in vivo glioblastoma data with other ML algorithms have reported higher sensitivity measures (Manni et al. [94], Fabelo et al. [92,93]).

Both in vivo and ex vivo models serve important roles in neuro-oncology where in vivo models can guide brain tumor resection in real-time while ex vivo models are a useful help for the neuropathologist. Another main reason for result variation across these studies is the small number of included patients as machine learning algorithms require considerable amount of data to be specific. The current lack of robust discrimination between healthy and tumor tissue therefore limits the generalization of these studies for clinical use.

4.3. Optical Coherence Tomography

Earlier work done in the OCT field has relied on estimating the tissue optical attenuation coefficient from the OCT signal to distinguish between cancerous and healthy tissue, with Kut et al. [96] showcasing impressive diagnostic precision in ex vivo tissue. For patients with higher-grade tumors, the achieved sensitivity/specificity reached 92%/100%, while for low-grade tumors, sensitivity/specificity values were 100%/80% (Kut et al. [96]). However, this approach requires sacrificing spatial resolution to boost signal quality. To overcome this, alternative approaches have been used in recent years.

One such approach was conducted by Juarez-Chambi et al. [97] where they used a novel AI-assisted computational pipeline on in vivo glioma tissue to overcome the low spatial resolution limiting previous work. Their approach was able to differentiate between low-grade and high-grade gliomas with high precision.

Another novel approach was conducted by Yashin et al. [98] where they used a cross-polarization OCT (PS-OCT) approach which can detect both the light scattering and the polarization properties of the tissue, and thereby provide tissue-specific contrast and

better visualization of structures like myelinated nerve fibers [105]. The study achieved high diagnostic accuracy (87–88%) for differentiating white matter and tumor tissue. The experiments performed *in vivo* by Yashin et al. [98] also included a more heterogeneous mix including astrocytomas, glioblastomas and breast cancer metastasis and showed overall that cancerous tissue is characterized by a lower optical attenuation rate when compared to healthy white matter, findings also reported by Kut et al. [96].

Another major benefit for OCT technologies is their high processing speed, with newer approaches acquiring high-resolution images under 1 s (Juarez-Chambi et al. [97]). This time efficacy combined with high resolution makes them suitable for real-time *in situ* detection of brain cancer.

4.4. Diffuse Reflectance Spectroscopy

Lin et al. [99] (1) performed their study on a pediatric population and included major pediatric tumor types including pilocytic astrocytoma, ganglioglioma, and medulloblastoma, making the analyzed tumor tissue much more heterogeneous compared to other studies in the optical field which focus mainly on gliomas and glioblastomas. Their *intraoperative* setup with a handheld probe was able to distinguish between healthy and cancerous tissue, reporting that diffuse reflectance intensities between 600 and 800 nm were most effective for discrimination. However, the spectral analysis and classification methods used here did not include the entire spectral data, therefore not capturing the complete biological variation present in the tissue.

Further work in the field has been able to improve on this setup with Du Le et al. [101] combining fluorescence spectroscopy and DRS to differentiate between low-grade gliomas and glioblastoma multiforme, with a reported 100% sensitivity in *ex vivo* tissue. They reported the distinguishing feature to be higher scattering and absorption coefficients in glioblastoma multiforme compared to low-grade gliomas.

Elmi-Terander et al. studied differentiation between low-grade gliomas and healthy brain tissue specifically [22]. Classification using random forest yielded a sensitivity of 82.0% and a specificity of 82.7% for the detection of low-grade gliomas. Their method involved a fitting model for estimating biological constituents in addition to scattering and absorption coefficients.

4.5. Applications

Optical methods are emerging as a new and innovative way for *intraoperative* tumor detection [20,22]. Within the field of brain tumor surgery, there is a demand for improved ways of detecting tumor tissue *intraoperatively* so that a maximal extent of resection can be achieved. Improved extent of resection can result in decreased tumor recurrence which in turn can result in decreased morbidity and mortality [1]. Furthermore, optical methods have the potential to improve the precision and diagnostic rapidity of brain tumor biopsies, making brain biopsies less harmful [106]. These optical methods are also under investigation for a wider range of implementations in neurosurgery including studying cerebrovascular plaque composition [107], enhancing precision in functional neurosurgery, *intraoperative* microcirculation measurements [108] and diagnostics. Optical methods have the potential to revolutionize surgery and many more applications are yet to be explored.

However, for the optical methods to advance from an experimental stage to clinical *intraoperative* practice, it is essential that studies are performed on a wide variety of tumor types, to capture data on the precision of various system-setups, diagnostic algorithms, and spectral signatures of tissues. This review showed that RS had the largest number of studies and the most inclusive range of tumor types, hence being the most mature of the optical methods. As for HIS and OCT the range of tumor type representation was limited.

Most of the research conducted in the field suffers from tumor homogeneity. Overall, glioblastoma multiforme was the most investigated tumor type. Breakthroughs in the surgical treatment of this highly malignant and infiltrative tumor [109] would have a major impact on the field, leading to an expected high research incentive. Surprisingly, a range

of studies also investigated meningiomas, which are common extra-axial tumors with no infiltrative features. Adhering to relevant research questions within the field is key to highlighting the utility and potential benefit of a novel technology. Hence, future studies ought to focus more on invasive or intraparenchymal tumors that are difficult to distinguish from normal surrounding brain tissue.

Another major drawback in most studies is the small number of tissue samples included. This needs to change going forward particularly as AI is progressively utilized for outcome prediction. Future work needs to address these issues in a constructive way. For example, while training models on heterogeneous tumor types is very important, studies training their models on many different tumor types without increasing the sample size, risk limiting the generalizability of the results.

4.6. In Vivo/Ex Vivo Setups

There are two ways for the discussed optical systems to be used intraoperatively: (1) through a hand-held fiber optic probe that is contact-based and analyzes the tissue in vivo, and (2) through a stationary device that is set up near the operating table and that analyzes ex vivo tissue with instant feedback to the surgeon. The latter essentially replaces a pathologist, cutting down on the logistical hurdles of preserved tissue transportation to a pathology lab, and minimizing the intraoperative waiting time for histopathological analysis.

In the case of Raman-based technologies, studies by Jermyn et al. [81,82,84] used a hand-held fiber optic probe to perform a contact-based spectral analysis of brain tissue in vivo while Hollon et al. [75] (1) used a “stimulated Raman histology” system that classified images with convolutional neural networks. Similar in vivo/ex vivo setups exist for DRS and OCT.

As most research performed so far has been ex vivo, more in vivo data is needed. For more in vivo contact-probe-based studies to be performed, a high ethical standard must be upheld; and for this, more evidence of the safety, precision and reliability of the technologies is needed. Overcoming challenges in future in vivo setups is therefore crucial, including the standardization of probe stability, addressing variations in probe contact pressure that may impact spectral measurements, minimizing signal loss from the probe fiber, and overcoming reduced performance caused by the presence of blood in the measurement field.

Another main constraint linked to the regular clinical application of these technologies is the necessity for a well-established illumination setup to minimize interference from external light sources in the recorded signal. Optical filters and other novel engineering solutions can be used to limit the effect of these sources when designing future operating rooms.

4.7. Sensitivity and Specificity

It is important to acknowledge that the sensitivity and specificity of these optic methods for detecting tumor tissue needs to be adapted to the specific surgical procedure for which they will be used. For example, when operating in proximity to eloquent areas of the brain, a specific (low false-positive rate) system that reserves the surrounding healthy tissue is desired. Similarly, in the case of brain tumor biopsies, systems of high specificity are desired, as the aim is to specifically sample the tumor tissue. On the other hand, operating on highly invasive tumors, where the loss of surrounding brain tissue has a negligible impact, a high sensitivity (low false negative rate) would be desired.

4.8. Limitations

First, our systematic review focused on four of the most popular optical methods, leaving out less established tools and limiting the generalizability of the findings to the whole field of optics. In addition, it is undeniable that the field of optical methods in neurosurgery is still in its initial stages. For that reason, the external validity of the findings

highlighted in this review is limited. Finally, due to the methodological heterogeneity between studies, a meta-analysis could not be performed.

4.9. Future Perspectives

Despite huge technical advances within the field of neurosurgery regarding navigation and tissue identification, several challenges remain. To date, no widely used tools to enhance surgeon's vision and provide immediate tissue diagnostic are available. The naked eye, even equipped with the surgical microscope, cannot differentiate between diffuse growing tumors and healthy brain tissue. Intraoperative pathological diagnostics is slow and valuable intraoperative time is lost for that purpose. Photosensitive drugs and contrast agents are not without side effects and limitations. The phenomenon of brain shift adds to the difficulty of navigation and tissue recognition. We believe that incorporation of intrinsic optical technologies could provide parts of the required solutions. However, these technologies generate huge amounts of data requiring the ability to handle and interpret big data simultaneously with the surgical procedure. The future research efforts will therefore require collaboration between neurosurgeons, computer scientists, experts in optical technologies and navigation. One such initiative is the project STRATUM [110], a 3D decision support tool for brain tumor surgery within the European Union Horizon Program. However, more international and interdisciplinary efforts are required to successfully progress this field.

5. Conclusions

In this systematic review, the characteristics of the optical systems, tumor types and the outcomes in terms of sensitivity, specificity and accuracy have been summarized. The results show that there is evidence for all four optical methods being promising for identification of brain tumors and healthy tissue. Raman spectroscopy is currently the most explored method. More studies, however, are needed for the technologies to move from an experimental stage to an intraoperative clinical setting.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/jcm13092676/s1>, Table S1: PRISMA checklist; Table S2: Search strategy, Table S3: Data extraction, Table S4: Characteristics of studies involving Raman Spectroscopy, Table S5: Table listing the characteristics of all included studies investigating HSI, Table S6: Table listing the characteristics of all included studies investigating OCT, Table S7: Table listing the characteristics of all included studies investigating DRS.

Author Contributions: Conceptualization, G.B., M.A., V.G.E.-H., E.E. and A.E.-T.; methodology, G.B., M.A., V.G.E.-H., E.E. and A.E.-T.; formal analysis, G.B. and M.A.; data curation, G.B. and M.A.; writing—original draft preparation, G.B., M.A. and A.A.; writing—review and editing, G.B., M.A., V.G.E.-H., A.A., M.G., A.B., M.S.L., F.M., E.E. and A.E.-T.; supervision, M.S.L., F.M., E.E. and A.E.-T. All authors have read and agreed to the published version of the manuscript.

Funding: AET is supported by Region Stockholm in a clinical research appointment.

Institutional Review Board Statement: Ethical approval was not required for this systematic review.

Informed Consent Statement: Not applicable.

Data Availability Statement: The excel file used to conduct this systematic review can be provided by the corresponding author upon reasonable demand.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Hervey-Jumper, S.L.; Berger, M.S. Maximizing safe resection of low- and high-grade glioma. *J. Neurooncol.* **2016**, *130*, 269–282. [[CrossRef](#)] [[PubMed](#)]
2. Brown, T.J.; Brennan, M.C.; Li, M.; Church, E.W.; Brandmeir, N.J.; Rakszawski, K.L.; Patel, A.S.; Rizk, E.B.; Suki, D.; Sawaya, R.; et al. Association of the Extent of Resection with Survival in Glioblastoma A Systematic Review and Meta-analysis Supplemental content at jamaoncology.com. *JAMA Oncol.* **2016**, *2*, 1460–1469. [[CrossRef](#)]

3. Putavet, D.A.; de Keizer, P.L.J. Residual Disease in Glioma Recurrence: A Dangerous Liaison with Senescence. *Cancers* **2021**, *13*, 1560. [[CrossRef](#)] [[PubMed](#)]
4. Uppstrom, T.J.; Singh, R.; Hadjigeorgiou, G.F.; Magge, R.; Ramakrishna, R. Repeat surgery for recurrent low-grade gliomas should be standard of care. *Clin. Neurol. Neurosurg.* **2016**, *151*, 18–23. [[CrossRef](#)] [[PubMed](#)]
5. Molina, E.S.; Schipmann, S.; Stummer, W. Maximizing safe resections: The roles of 5-aminolevulinic acid and intraoperative MR imaging in glioma surgery—Review of the literature. *Neurosurg. Rev.* **2019**, *42*, 197. [[CrossRef](#)]
6. Stepp, H.; Stummer, W. 5-ALA in the management of malignant glioma. *Lasers Surg. Med.* **2018**, *50*, 399–419. [[CrossRef](#)] [[PubMed](#)]
7. Stummer, W.; Stocker, S.; Wagner, S.; Stepp, H.; Fritsch, C.; Goetz, C.; Goetz, A.E.; Kiefmann, R.; Reulen, H.J. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid- induced porphyrin fluorescence. *Neurosurgery* **1998**, *42*, 518–526. [[PubMed](#)]
8. Sastry, R.; Bi, W.L.; Pieper, S.; Frisken, S.; Kapur, T.; Wells, W.; Golby, A.J. Applications of Ultrasound in the Resection of Brain Tumors. *J. Neuroimaging* **2017**, *27*, 5–15. [[CrossRef](#)]
9. Bisdas, S.; Roder, C.; Ernemann, U.; Tatagiba, M.S. Intraoperative MR Imaging in Neurosurgery. *Clin. Neuroradiol.* **2015**, *25*, 237–244. [[CrossRef](#)]
10. Nimsky, C.; Ganslandt, O.; Cerny, S.; Hastreiter, P.; Greiner, G.; Fahlbusch, R. Quantification of, Visualization of, and Compensation for Brain Shift Using Intraoperative Magnetic Resonance Imaging. *Neurosurgery* **2000**, *47*, 1070–1080. [[CrossRef](#)]
11. Dickhaus, H.; Ganser, K.A.; Staubert, A.; Bonsanto, M.M.; Wirtz, C.R.; Tronnier, V.M.; Kunze, S. Quantification of brain shift effects by MR-imaging. In Proceedings of the 19th Annual International Conference of the IEEE Engineering in Medicine and Biology Society. “Magnificent Milestones and Emerging Opportunities in Medical Engineering” (Cat. No.97CH36136), Chicago, IL, USA, 30 October–2 November 1997; pp. 491–494.
12. Dixon, L.; Lim, A.; Grech-Sollars, M.; Nandi, D.; Camp, S. Intraoperative ultrasound in brain tumor surgery: A review and implementation guide. *Neurosurg. Rev.* **2022**, *45*, 2503–2515. [[CrossRef](#)] [[PubMed](#)]
13. Hadjipanayis, C.G.; Widhalm, G.; Stummer, W. What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas? *Neurosurgery* **2015**, *77*, 663–673. [[CrossRef](#)]
14. Micko, A.; Rapoport, B.I.; Youngerman, B.E.; Fong, R.P.; Kosty, J.; Brunswick, A.; Shahrestani, S.; Zada, G.; Schwartz, T.H. Limited utility of 5-ALA optical fluorescence in endoscopic endonasal skull base surgery: A multicenter retrospective study. *J. Neurosurg.* **2020**, *135*, 535–541. [[CrossRef](#)]
15. Molinaro, A.M.; Hervey-Jumper, S.; Morshed, R.A.; Young, J.; Han, S.J.; Chunduru, P.; Zhang, Y.; Phillips, J.J.; Shai, A.; Lafontaine, M.; et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor with Survival within Molecular Subgroups of Patients with Newly Diagnosed Glioblastoma. *JAMA Oncol.* **2020**, *6*, 495. [[CrossRef](#)] [[PubMed](#)]
16. DePaoli, D.; Lemoine, É.; Ember, K.; Parent, M.; Prud’homme, M.; Cantin, L.; Petrecca, K.; Leblond, F.; Côté, D.C. Rise of Raman spectroscopy in neurosurgery: A review. *J. Biomed. Opt.* **2020**, *25*, 1. [[CrossRef](#)]
17. Yashin, K.; Bonsanto, M.M.; Achkasova, K.; Zolotova, A.; Wael, A.-M.; Kiseleva, E.; Moiseev, A.; Medyanik, I.; Kravets, L.; Huber, R.; et al. OCT-Guided Surgery for Gliomas: Current Concept and Future Perspectives. *Diagnostics* **2022**, *12*, 335. [[CrossRef](#)]
18. Fujimoto, J.G.; Pitris, C.; Boppart, S.A.; Brezinski, M.E. Optical Coherence Tomography: An Emerging Technology for Biomedical Imaging and Optical Biopsy. *Neoplasia* **2000**, *2*, 9–25. [[CrossRef](#)] [[PubMed](#)]
19. Lu, G.; Fei, B. Medical hyperspectral imaging: A review. *J. Biomed. Opt.* **2014**, *19*, 010901. [[CrossRef](#)]
20. Valdés, P.A.; Roberts, D.W.; Lu, F.-K.K.; Golby, A.; Valdés, P.A.; Roberts, D.W.; Lu, F.-K.K.; Golby, A. Optical technologies for intraoperative neurosurgical guidance. *Neurosurg. Focus* **2016**, *40*, E8. [[CrossRef](#)]
21. Grinvald, A.; Lieke, E.; Frostig, R.D.; Gilbert, C.D.; Wiesel, T.N. Functional architecture of cortex revealed. *Nature* **1986**, *324*, 361–363. [[CrossRef](#)]
22. Skyrman, S.; Burström, G.; Lai, M.; Manni, F.; Hendriks, B.; Frostell, A.; Edström, E.; Persson, O.; Elmi-Terander, A. Diffuse reflectance spectroscopy sensor to differentiate between glial tumor and healthy brain tissue: A proof-of-concept study. *Biomed. Opt. Express* **2022**, *13*, 6470. [[CrossRef](#)] [[PubMed](#)]
23. Skyrman, S.; Burström, G.; Aspegren, O.; Babic, D.; Lucassen, G.; Edström, E.; Arnberg, F.; Ohlsson, M.; Mueller, M.; Elmi-Terander, A.; et al. Clot composition characterization using diffuse reflectance spectroscopy in acute ischemic stroke. *Biomed. Opt. Express* **2022**, *13*, 3311. [[CrossRef](#)] [[PubMed](#)]
24. Raman, C.V.; Krishnan, K.S. A New Type of Secondary Radiation. *Nature* **1928**, *121*, 501–502. [[CrossRef](#)]
25. Kong, K.; Kendall, C.; Stone, N.; Notingher, I. Raman spectroscopy for medical diagnostics—From in-vitro biofluid assays to in-vivo cancer detection. *Adv. Drug Deliv. Rev.* **2015**, *89*, 121–134. [[CrossRef](#)] [[PubMed](#)]
26. Jones, R.R.; Hooper, D.C.; Zhang, L.; Wolverson, D.; Valev, V.K. Raman Techniques: Fundamentals and Frontiers. *Nanoscale Res. Lett.* **2019**, *14*, 231. [[CrossRef](#)] [[PubMed](#)]
27. Butler, H.J.; Ashton, L.; Bird, B.; Cinque, G.; Curtis, K.; Dorney, J.; Esmonde-White, K.; Fullwood, N.J.; Gardner, B.; Martin-Hirsch, P.L.; et al. Using Raman spectroscopy to characterize biological materials. *Nat. Protoc.* **2016**, *11*, 664–687. [[CrossRef](#)]
28. Kast, R.; Auner, G.; Yurgelevic, S.; Broadbent, B.; Raghunathan, A.; Poisson, L.M.; Mikkelsen, T.; Rosenblum, M.L.; Kalkanis, S.N. Identification of regions of normal grey matter and white matter from pathologic glioblastoma and necrosis in frozen sections using Raman imaging. *J. Neurooncol.* **2015**, *125*, 287–295. [[CrossRef](#)]

29. Desroches, J.; Jermyn, M.; Mok, K.; Lemieux-Leduc, C.C.; Mercier, J.; St-Arnaud, K.; Urmey, K.; Guiot, M.-C.; Marple, E.; Petrecca, K.; et al. Characterization of a Raman spectroscopy probe system for intraoperative brain tissue classification. *Biomed. Opt. Express* **2015**, *6*, 2380–2397. [[CrossRef](#)]
30. Uckermann, O.; Yao, W.; Juratli, T.A.; Galli, R.; Leipnitz, E.; Meinhardt, M.; Koch, E.; Schackert, G.; Steiner, G.; Kirsch, M. IDH1 mutation in human glioma induces chemical alterations that are amenable to optical Raman spectroscopy. *J. Neurooncol.* **2018**, *139*, 261–268. [[CrossRef](#)]
31. Orringer, D.A.; Pandian, B.; Niknafs, Y.S.; Hollon, T.C.; Boyle, J.; Lewis, S.; Garrard, M.; Hervey-Jumper, S.L.; Garton, H.J.L.; Maher, C.O.; et al. Rapid intraoperative histology of unprocessed surgical specimens via fibre-laser-based stimulated Raman scattering microscopy. *Nat. Biomed. Eng.* **2017**, *1*, 0027. [[CrossRef](#)]
32. Hollon, T.; Orringer, D.A. Label-free brain tumor imaging using Raman-based methods. *J. Neurooncol.* **2021**, *151*, 393–402. [[CrossRef](#)] [[PubMed](#)]
33. Desroches, J.; Jermyn, M.; Pinto, M.; Picot, F.; Tremblay, M.-A.; Obaid, S.; Marple, E.; Urmey, K.; Trudel, D.; Soulez, G.; et al. A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy. *Sci. Rep.* **2018**, *8*, 1792. [[CrossRef](#)] [[PubMed](#)]
34. Jermyn, M.; Mok, K.; Mercier, J.; Desroches, J.; Pichette, J.; Saint-Arnaud, K.; Bernstein, L.; Guiot, M.-C.; Petrecca, K.; Leblond, F. Intraoperative brain cancer detection with Raman spectroscopy in humans. *Sci. Transl. Med.* **2015**, *7*, 274ra19. [[CrossRef](#)] [[PubMed](#)]
35. Baria, E.; Giordano, F.; Guerrini, R.; Caporalini, C.; Buccoliero, A.M.; Cicchi, R.; Pavone, F.S. Dysplasia and tumor discrimination in brain tissues by combined fluorescence, Raman, and diffuse reflectance spectroscopies. *Biomed. Opt. Express* **2023**, *14*, 1256. [[CrossRef](#)]
36. Li, Q.; He, X.; Wang, Y.; Liu, H.; Xu, D.; Guo, F. Review of spectral imaging technology in biomedical engineering: Achievements and challenges. *J. Biomed. Opt.* **2013**, *18*, 100901. [[CrossRef](#)] [[PubMed](#)]
37. Kamruzzaman, M.; Sun, D.-W. Introduction to Hyperspectral Imaging Technology. In *Computer Vision Technology for Food Quality Evaluation*; Elsevier: Amsterdam, The Netherlands, 2016; pp. 111–139.
38. Shapey, J.; Xie, Y.; Nabavi, E.; Bradford, R.; Saeed, S.R.; Ourselin, S.; Vercauteren, T. Intraoperative multispectral and hyperspectral label-free imaging: A systematic review of in vivo clinical studies. *J. Biophotonics* **2019**, *12*, e201800455. [[CrossRef](#)]
39. Fabelo, H.; Ortega, S.; Kabwama, S.; Callico, G.M.; Bulters, D.; Szolna, A.; Pineiro, J.F.; Sarmiento, R. HELICoiD Project: A New Use of Hyperspectral Imaging for Brain Cancer Detection in Real-Time during Neurosurgical Operations. In *Proceedings Volume 9860, Hyperspectral Imaging Sensors: Innovative Applications and Sensor Standards 2016*; Bannan, D.P., Ed.; SPIE: Bellingham, WA, USA, 2016; p. 986002.
40. Bravo, J.J.; Olson, J.D.; Davis, S.C.; Roberts, D.W.; Paulsen, K.D.; Kanick, S.C. Hyperspectral data processing improves PpIX contrast during fluorescence guided surgery of human brain tumors. *Sci. Rep.* **2017**, *7*, 9455. [[CrossRef](#)] [[PubMed](#)]
41. Best, S.L.; Thapa, A.; Holzer, M.J.; Jackson, N.; Mir, S.A.; Cadeddu, J.A.; Zuzak, K.J. Minimal Arterial In-flow Protects Renal Oxygenation and Function During Porcine Partial Nephrectomy: Confirmation by Hyperspectral Imaging. *Urology* **2011**, *78*, 961–966. [[CrossRef](#)] [[PubMed](#)]
42. Zuzak, K.J.; Naik, S.C.; Alexandrakis, G.; Hawkins, D.; Behbehani, K.; Livingston, E. Intraoperative bile duct visualization using near-infrared hyperspectral video imaging. *Am. J. Surg.* **2008**, *195*, 491–497. [[CrossRef](#)]
43. Vignali, L.; Solinas, E.; Emanuele, E. Research and Clinical Applications of Optical Coherence Tomography in Invasive Cardiology: A Review. *Curr. Cardiol. Rev.* **2014**, *10*, 369–376. [[CrossRef](#)]
44. Wan, B.; Ganier, C.; Du-Harpur, X.; Harun, N.; Watt, F.M.; Patalay, R.; Lynch, M.D. Applications and future directions for optical coherence tomography in dermatology. *Br. J. Dermatol.* **2021**, *184*, 1014–1022. [[CrossRef](#)] [[PubMed](#)]
45. Fan, Y.; Xia, Y.; Zhang, X.; Sun, Y.; Tang, J.; Zhang, L.; Liao, H. Optical coherence tomography for precision brain imaging, neurosurgical guidance and minimally invasive theranostics. *Biosci. Trends* **2018**, *12*, 12–23. [[CrossRef](#)] [[PubMed](#)]
46. Fercher, A.F.; Hitzinger, C.K.; Drexler, W.; Kamp, G.; Sattmann, H. In vivo optical coherence tomography. *Am. J. Ophthalmol.* **1993**, *116*, 113–114. [[CrossRef](#)] [[PubMed](#)]
47. Mokbul, M.I. Optical Coherence Tomography: Basic Concepts and Applications in Neuroscience Research. *J. Med. Eng.* **2017**, *2017*, 3409327. [[PubMed](#)]
48. Podoleanu, A.G. Optical coherence tomography. *J. Microsc.* **2012**, *247*, 209–219. [[CrossRef](#)]
49. Keles, G.E.; Lundin, D.A.; Lamborn, K.R.; Chang, E.F.; Ojemann, G.; Berger, M.S. Intraoperative subcortical stimulation mapping for hemispheric perirolandic gliomas located within or adjacent to the descending motor pathways: Evaluation of morbidity and assessment of functional outcome in 294 patients. *J. Neurosurg.* **2004**, *100*, 369–375. [[CrossRef](#)] [[PubMed](#)]
50. Sun, C.; Lee, K.K.C.; Vuong, B.; Cusimano, M.; Brukson, A.; Mariampillai, A.; Standish, B.A.; Yang, V.X.D. Neurosurgical hand-held optical coherence tomography (OCT) forward-viewing probe. *Proc. SPIE* **2012**, *8207*, 82074V.
51. Lankenau, E.M.; Krug, M.; Oelckers, S.; Schrage, N.; Just, T.; Hüttmann, G. iOCT with surgical microscopes: A new imaging during microsurgery. *Adv. Opt. Technol.* **2013**, *2*, 233–239. [[CrossRef](#)]
52. Bydlon, T.M.; Nachabé, R.; Ramanujam, N.; Sterenborg, H.J.C.M.; Hendriks, B.H.W. Chromophore based analyses of steady-state diffuse reflectance spectroscopy: Current status and perspectives for clinical adoption. *J. Biophotonics* **2015**, *8*, 9–24. [[CrossRef](#)]
53. Akter, S.; Hossain, M.G.; Nishidate, I.; Hazama, H.; Awazu, K. Medical applications of reflectance spectroscopy in the diffusive and sub-diffusive regimes. *J. Near Infrared Spectrosc.* **2018**, *26*, 337–350. [[CrossRef](#)]

54. Iop, A.; El-Hajj, V.G.; Gharios, M.; De Giorgio, A.; Monetti, F.M.; Edström, E.; Elmi-Terander, A.; Romero, M. Extended Reality in Neurosurgical Education: A Systematic Review. *Sensors* **2022**, *22*, 6067. [[CrossRef](#)] [[PubMed](#)]
55. Lai, M.; Skyrman, S.; Kor, F.; Homan, R.; Babic, D.; Edström, E.; Persson, O.; Burström, G.; Elmi-Terander, A.; Hendriks, B.H.W.; et al. Development of a CT-compatible anthropomorphic skull phantom for surgical planning, training, and simulation. *Proc. SPIE* **2021**, *11601*, 43–52. [[CrossRef](#)]
56. Skyrman, S.; Lai, M.; Edström, E.; Burström, G.; Förander, P.; Homan, R.; Kor, F.; Holthuizen, R.; Hendriks, B.H.W.; Persson, O.; et al. Augmented reality navigation for cranial biopsy and external ventricular drain insertion. *Neurosurg. Focus* **2021**, *51*, E7. [[CrossRef](#)] [[PubMed](#)]
57. El-Hajj, V.G.; Segerlind, J.P.; Burström, G.; Edström, E.; Elmi-Terander, A. Current knowledge on spinal meningiomas: A systematic review protocol. *BMJ Open* **2022**, *12*, e061614. [[CrossRef](#)] [[PubMed](#)]
58. El-Hajj, V.G.; Pettersson-Segerlind, J.; Fletcher-Sandersjö, A.; Edström, E.; Elmi-Terander, A. Current Knowledge on Spinal Meningiomas Epidemiology, Tumor Characteristics and Non-Surgical Treatment Options: A Systematic Review and Pooled Analysis (Part 1). *Cancers* **2022**, *14*, 6251. [[CrossRef](#)] [[PubMed](#)]
59. El-Hajj, V.G.; Pettersson-Segerlind, J.; Fletcher-Sandersjö, A.; Edström, E.; Elmi-Terander, A. Current Knowledge on Spinal Meningiomas-Surgical Treatment, Complications, and Outcomes: A Systematic Review and Meta-Analysis (Part 2). *Cancers* **2022**, *14*, 6221. [[CrossRef](#)]
60. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. *Syst. Rev.* **2016**, *5*, 1–10. [[CrossRef](#)] [[PubMed](#)]
61. Tatter, C.; El-Hajj, V.G.; Fletcher-Sandersjö, A.; Edström, E.; Elmi-Terander, A. Radiographic measurements for the prediction of dysphagia after occipitocervical fusion: A systematic review. *Acta Neurochir.* **2023**, *165*, 1161–1170. [[CrossRef](#)] [[PubMed](#)]
62. Stables, R.; Clemens, G.; Butler, H.J.; Ashton, K.M.; Brodbelt, A.; Dawson, T.P.; Fullwood, L.M.; Jenkinson, M.D.; Baker, M.J. Feature driven classification of Raman spectra for real-time spectral brain tumour diagnosis using sound. *Analyst* **2017**, *142*, 98–109. [[CrossRef](#)]
63. Livermore, L.J.; Isabelle, M.; Bell, I.M.; Edgar, O.; Voets, N.L.; Stacey, R.; Ansorge, O.; Vallance, C.; Plaha, P. Raman spectroscopy to differentiate between fresh tissue samples of glioma and normal brain: A comparison with 5-ALA-induced fluorescence-guided surgery. *J. Neurosurg.* **2021**, *132*, 469–479. [[CrossRef](#)]
64. Sun, J.J.; Fang, H.; Zhang, Z.Q.; Chen, M.L.; Tian, J.J.; Chen, L.; Zou, X.; Yin, H.C.; Yin, J. Detection of glioma by surface-enhanced Raman scattering spectra with optimized mathematical methods. *J. Raman Spectrosc.* **2019**, *50*, 1130–1140. [[CrossRef](#)]
65. Leslie, D.G.; Kast, R.E.; Poulik, J.M.; Rabah, R.; Sood, S.; Auner, G.W.; Klein, M.D.; Kast, R.E.; Rabah, R.; Reisner, L.; et al. Identification of pediatric brain neoplasms using Raman spectroscopy. *Pediatr. Neurosurg.* **2012**, *48*, 109–117. [[CrossRef](#)] [[PubMed](#)]
66. Aguiar, R.P.; Falcão, E.T.; Pasqualucci, C.A.; Silveira, L.J.; Falcao, E.T.; Pasqualucci, C.A.; Silveira, L.J. Use of Raman spectroscopy to evaluate the biochemical composition of normal and tumoral human brain tissues for diagnosis. *Lasers Med. Sci.* **2020**, *37*, 121–133. [[CrossRef](#)]
67. Koljenović, S.; Schut, T.B.; Vincent, A.; Kros, J.M.; Puppels, G.J.; Koljenovic, S.; Schut, T.B.; Vincent, A.; Kros, J.M.; Puppels, G.J. Detection of meningioma in dura mater by Raman spectroscopy. *Anal. Chem.* **2005**, *77*, 7958–7965. [[CrossRef](#)]
68. Koljenović, S.; Choo-Smith, L.-P.; Schut, T.C.B.; Kros, J.M.; van den Berge, H.J.; Puppels, G.J.; Koljenovic, S.; Choo-Smith, L.-P.; Schut, T.C.B.; Kros, J.M.; et al. Discriminating vital tumor from necrotic tissue in human glioblastoma tissue samples by Raman spectroscopy. *Lab. Investig.* **2002**, *82*, 1265–1277. [[CrossRef](#)]
69. Riva, M.; Sciortino, T.; Secoli, R.; D’Amico, E.; Moccia, S.; Fernandes, B.; Nibali, M.C.; Gay, L.; Rossi, M.; De Momi, E.; et al. Glioma biopsies Classification Using Raman Spectroscopy and Machine Learning Models on Fresh Tissue Samples. *Cancers* **2021**, *13*, 1073. [[CrossRef](#)] [[PubMed](#)]
70. Sciortino, T.; Secoli, R.; d’Amico, E.; Moccia, S.; Nibali, M.C.; Gay, L.; Rossi, M.; Pecco, N.; Castellano, A.; De Momi, E.; et al. Raman Spectroscopy and Machine Learning for IDH Genotyping of Unprocessed Glioma Biopsies. *Cancers* **2021**, *13*, 4196. [[CrossRef](#)] [[PubMed](#)]
71. Kopec, M.; Blaszczyk, M.; Radek, M.; Abramczyk, H. Raman imaging and statistical methods for analysis various type of human brain tumors and breast cancers. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* **2021**, *262*, 120091. [[CrossRef](#)] [[PubMed](#)]
72. Jelke, F.; Mirizzi, G.; Borgmann, F.K.; Husch, A.; Slimani, R.; Klamminger, G.G.; Klein, K.; Mombaerts, L.; Gérardy, J.-J.; Mittelbronn, M.; et al. Intraoperative discrimination of native meningioma and dura mater by Raman spectroscopy. *Sci. Rep.* **2021**, *11*, 23583. [[CrossRef](#)]
73. Pekmezci, M.; Morshed, R.A.; Chundururu, P.; Pandian, B.; Young, J.; Villanueva-Meyer, J.E.; Tihan, T.; Sloan, E.A.; Aghi, M.K.; Molinaro, A.M.; et al. Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology. *Sci. Rep.* **2021**, *11*, 12162. [[CrossRef](#)]
74. Bury, D.; Morais, C.L.M.; Martin, F.L.; Lima, K.M.G.; Ashton, K.M.; Baker, M.J.; Dawson, T.P. Discrimination of fresh frozen non-tumour and tumour brain tissue using spectrochemical analyses and a classification model. *Br. J. Neurosurg.* **2020**, *34*, 40–45. [[CrossRef](#)] [[PubMed](#)]
75. Hollon, T.C.; Pandian, B.; Adapa, A.R.; Urias, E.; Save, A.V.; Khalsa, S.S.S.; Eichberg, D.G.; D’Amico, R.S.; Farooq, Z.U.; Lewis, S.; et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. *Nat. Med.* **2020**, *26*, 52–58. [[CrossRef](#)] [[PubMed](#)]

76. Bovenkamp, D.; Micko, A.; Puls, J.; Placzek, F.; Hoftberger, R.; Vila, G.; Leitgeb, R.; Drexler, W.; Andreada, M.; Wolfsberger, S.; et al. Line Scan Raman Microspectroscopy for Label-Free Diagnosis of Human Pituitary Biopsies. *Molecules* **2019**, *24*, 3577. [[CrossRef](#)] [[PubMed](#)]
77. Morais, C.L.M.; Lilo, T.; Ashton, K.M.; Davis, C.; Dawson, T.P.; Gurusinghe, N.; Martin, F.L. Determination of meningioma brain tumour grades using Raman microspectroscopy imaging. *Analyst* **2019**, *144*, 7024–7031. [[CrossRef](#)] [[PubMed](#)]
78. Galli, R.; Meinhardt, M.; Koch, E.; Schackert, G.; Steiner, G.; Kirsch, M.; Uckermann, O. Rapid Label-Free Analysis of Brain Tumor Biopsies by Near Infrared Raman and Fluorescence Spectroscopy—A Study of 209 Patients. *Front. Oncol.* **2019**, *9*, 1165. [[CrossRef](#)]
79. Bury, D.; Faust, G.; Paraskevaidi, M.; Ashton, K.M.; Dawson, T.P.; Martin, F.L. Phenotyping Metastatic Brain Tumors Applying Spectrochemical Analyses: Segregation of Different Cancer Types. *Anal. Lett.* **2019**, *52*, 575–587. [[CrossRef](#)]
80. Hollon, T.C.; Lewis, S.; Pandian, B.; Niknafs, Y.S.; Garrard, M.R.; Garton, H.; Maher, C.O.; McFadden, K.; Snuderl, M.; Lieberman, A.P.; et al. Rapid Intraoperative Diagnosis of Pediatric Brain Tumors Using Stimulated Raman Histology. *Cancer Res.* **2018**, *78*, 278–289. [[CrossRef](#)]
81. Jermyn, M.; Mercier, J.; Aubertin, K.; Desroches, J.; Urme, K.; Karamchandiani, J.; Marple, E.; Guiot, M.-C.C.; Leblond, F.; Petrecca, K. Highly Accurate Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy. *Cancer Res.* **2017**, *77*, 3942–3950. [[CrossRef](#)]
82. Jermyn, M.; Desroches, J.; Mercier, J.; St-Arnaud, K.; Guiot, M.C.; Leblond, F.; Petrecca, K. Raman spectroscopy detects distant invasive brain cancer cells centimeters beyond MRI capability in humans. *Biomed. Opt. Express* **2016**, *7*, 5129–5137. [[CrossRef](#)]
83. Liu, T.; Chen, C.S.; Shi, X.Z.; Liu, C.Y. Evaluation of Raman spectra of human brain tumor tissue using the learning vector quantization neural network. *Laser Phys.* **2016**, *26*, 055606. [[CrossRef](#)]
84. Jermyn, M.; Desroches, J.; Mercier, J.; Tremblay, M.-A.; St-Arnaud, K.; Guiot, M.-C.; Petrecca, K.; Leblond, F. Neural networks improve brain cancer detection with Raman spectroscopy in the presence of operating room light artifacts. *J. Biomed. Opt.* **2016**, *21*, 94002. [[CrossRef](#)] [[PubMed](#)]
85. Ji, M.; Lewis, S.; Camelo-Piragua, S.; Ramkissoon, S.H.; Snuderl, M.; Venneti, S.; Fisher-Hubbard, A.; Garrard, M.; Fu, D.; Wang, A.C.; et al. Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy. *Sci. Transl. Med.* **2015**, *7*, 309ra163. [[CrossRef](#)] [[PubMed](#)]
86. Kalkanis, S.N.; Kast, R.E.; Rosenblum, M.L.; Mikkelsen, T.; Yurgelevic, S.M.; Nelson, K.M.; Raghunathan, A.; Poisson, L.M.; Auner, G.W. Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections. *J. Neurooncol.* **2014**, *116*, 477–485. [[CrossRef](#)] [[PubMed](#)]
87. Bergner, N.; Romeike, B.F.M.; Reichart, R.; Kalff, R.; Krafft, C.; Popp, J.U. Tumor margin identification and prediction of the primary tumor from brain metastases using FTIR imaging and support vector machines. *Analyst* **2013**, *138*, 3983–3990. [[CrossRef](#)] [[PubMed](#)]
88. Auner, A.W.; Kast, R.E.; Rabah, R.; Poulik, J.M.; Klein, M.D. Conclusions and data analysis: A 6-year study of Raman spectroscopy of solid tumors at a major pediatric institute. *Pediatr. Surg. Int.* **2013**, *29*, 129–140. [[CrossRef](#)] [[PubMed](#)]
89. Zhou, Y.; Liu, C.-H.; Wu, B.; Yu, X.; Cheng, G.; Zhu, K.; Wang, K.; Zhang, C.; Zhao, M.; Zong, R.; et al. Optical biopsy identification and grading of gliomas using label-free visible resonance Raman spectroscopy. *J. Biomed. Opt.* **2019**, *24*, 1. [[CrossRef](#)]
90. Urbanos, G.; Martin, A.; Vazquez, G.; Villanueva, M.; Villa, M.; Jimenez-Roldan, L.; Chavarrias, M.; Lagares, A.; Juarez, E.; Sanz, C. Supervised Machine Learning Methods and Hyperspectral Imaging Techniques Jointly Applied for Brain Cancer Classification. *Sensors* **2021**, *21*, 3827. [[CrossRef](#)]
91. Ortega, S.; Fabelo, H.; Camacho, R.; de la Luz Plaza, M.; Callico, G.M.; Sarmiento, R. Detecting brain tumor in pathological slides using hyperspectral imaging. *Biomed. Opt. Express* **2018**, *9*, 818–831. [[CrossRef](#)] [[PubMed](#)]
92. Fabelo, H.; Halicek, M.; Ortega, S.; Shahedi, M.; Szolna, A.; Pineiro, J.F.; Sosa, C.; O'Shanahan, A.J.; Bisshopp, S.; Espino, C.; et al. Deep Learning-Based Framework for In Vivo Identification of Glioblastoma Tumor using Hyperspectral Images of Human Brain. *Sensors* **2019**, *19*, 920. [[CrossRef](#)]
93. Fabelo, H.; Halicek, M.; Ortega, S.; Szolna, A.; Morera, J.; Sarmiento, R.; Callico, G.M.; Fei, B. Surgical Aid Visualization System for Glioblastoma Tumor Identification based on Deep Learning and In-Vivo Hyperspectral Images of Human Patients. *Proc. SPIE Int. Soc. Opt. Eng.* **2019**, *10951*, 254–264.
94. Manni, F.; van der Sommen, F.; Fabelo, H.; Zinger, S.; Shan, C.; Edstrom, E.; Elmi-Terander, A.; Ortega, S.; Callico, G.M.; de With, P.H.N. Hyperspectral Imaging for Glioblastoma Surgery: Improving Tumor Identification Using a Deep Spectral-Spatial Approach. *Sensors* **2020**, *20*, 6955. [[CrossRef](#)] [[PubMed](#)]
95. Möller, J.; Bartsch, A.; Lenz, M.; Tischoff, I.; Krug, R.; Welp, H.; Hofmann, M.R.; Schmieder, K.; Miller, D.; Moller, J.; et al. Applying machine learning to optical coherence tomography images for automated tissue classification in brain metastases. *Int. J. Comput. Assist. Radiol. Surg.* **2021**, *16*, 1517–1526. [[CrossRef](#)] [[PubMed](#)]
96. Kut, C.; Chaichana, K.L.; Xi, J.; Raza, S.M.; Ye, X.; McVeigh, E.R.; Rodriguez, F.J.; Quinones-Hinojosa, A.; Li, X. Detection of human brain cancer infiltration ex vivo and in vivo using quantitative optical coherence tomography. *Sci. Transl. Med.* **2015**, *7*, 292ra100. [[CrossRef](#)] [[PubMed](#)]
97. Juarez-Chambi, R.M.; Kut, C.; Rico-Jimenez, J.J.; Chaichana, K.L.; Xi, J.; Campos-Delgado, D.U.; Rodriguez, F.J.; Quinones-Hinojosa, A.; Li, X.; Jo, J.A. AI-Assisted In Situ Detection of Human Glioma Infiltration Using a Novel Computational Method for Optical Coherence Tomography. *Clin. Cancer Res.* **2019**, *25*, 6329–6338. [[CrossRef](#)] [[PubMed](#)]

98. Yashin, K.S.; Kiseleva, E.B.; Gubarkova, E.V.; Moiseev, A.A.; Kuznetsov, S.S.; Shilyagin, P.A.; Gelikonov, G.V.; Medyanik, I.A.; Kravets, L.Y.; Potapov, A.A.; et al. Cross-Polarization Optical Coherence Tomography for Brain Tumor Imaging. *Front. Oncol.* **2019**, *9*, 201. [CrossRef] [PubMed]
99. Lin, W.-C.; Sandberg, D.I.; Bhatia, S.; Johnson, M.; Oh, S.; Ragheb, J. Diffuse reflectance spectroscopy for in vivo pediatric brain tumor detection. *J. Biomed. Opt.* **2010**, *15*, 61709. [CrossRef] [PubMed]
100. Lin, W.-C.; Toms, S.A.; Johnson, M.; Jansen, E.D.; Mahadevan-Jansen, A. In Vivo Brain Tumor Demarcation Using Optical Spectroscopy. *Photochem. Photobiol.* **2001**, *73*, 396. [CrossRef]
101. Le, V.N.D.; Provias, J.; Murty, N.; Patterson, M.S.; Nie, Z.J.; Hayward, J.E.; Farrell, T.J.; McMillan, W.; Zhang, W.B.; Fang, Q.Y. Dual-modality optical biopsy of glioblastomas multiforme with diffuse reflectance and fluorescence: Ex vivo retrieval of optical properties. *J. Biomed. Opt.* **2017**, *22*, 341–354.
102. Majumder, S.K.; Gebhart, S.; Johnson, M.D.; Thompson, R.; Lin, W.C.; Mahadevan-Jansen, A. A probability-based spectroscopic diagnostic algorithm for simultaneous discrimination of brain tumor and tumor margins from normal brain tissue. *Appl. Spectrosc.* **2007**, *61*, 548–557. [CrossRef]
103. Lemoine, É.; Dallaire, F.; Yadav, R.; Agarwal, R.; Kadoury, S.; Trudel, D.; Guiot, M.-C.; Petrecca, K.; Leblond, F. Feature engineering applied to intraoperative in vivo Raman spectroscopy sheds light on molecular processes in brain cancer: A retrospective study of 65 patients. *Analyst* **2019**, *144*, 6517–6532. [CrossRef]
104. Abramczyk, H.; Imiela, A. The biochemical, nanomechanical and chemometric signatures of brain cancer. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* **2018**, *188*, 8–19. [CrossRef] [PubMed]
105. Baumann, B. Polarization Sensitive Optical Coherence Tomography: A Review of Technology and Applications. *Appl. Sci.* **2017**, *7*, 474. [CrossRef]
106. Desroches, J.; Lemoine, E.; Pinto, M.; Marple, E.; Urmey, K.; Diaz, R.; Guiot, M.-C.; Wilson, B.C.; Petrecca, K.; Leblond, F. Development and first in-human use of a Raman spectroscopy guidance system integrated with a brain biopsy needle. *J. Biophotonics* **2019**, *12*, e201800396. [CrossRef] [PubMed]
107. Skyrman, S.; Burström, G.; Aspegren, O.; Lucassen, G.; Elmi-Terander, A.; Edström, E.; Arnberg, F.; Ohlsson, M.; Mueller, M.; Andersson, T. Identifying clot composition using intravascular diffuse reflectance spectroscopy in a porcine model of endovascular thrombectomy. *J. Neurointerv. Surg.* **2021**, *14*, 1–7. [CrossRef]
108. Rejmstad, P.; Åkesson, G.; Åneman, O.; Wårdell, K. A laser Doppler system for monitoring cerebral microcirculation: Implementation and evaluation during neurosurgery. *Med. Biol. Eng. Comput.* **2016**, *54*, 123–131. [CrossRef]
109. Batash, R.; Asna, N.; Schaffer, P.; Francis, N.; Schaffer, M. Glioblastoma Multiforme, Diagnosis and Treatment; Recent Literature Review. *Curr. Med. Chem.* **2017**, *24*, 3002–3009. [CrossRef]
110. STRATUM—3D Decision Support Tool for Brain Tumor Surgery. Available online: <https://www.stratum-project.eu> (accessed on 28 April 2024).

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.